Key facts
- Bilihome’s last known valuation is $11.7M (Sep 2025).
- It has raised $2.7M; the latest was Later Stage VC in Sep 2025.
- Notable investors include Oost NL, NLC Health Ventures, Health Innovations.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Bilihome
- ·The full record, as it builds
Funding rounds
No funding rounds for Bilihome are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Bilihome
Developer of wearable phototherapy technology designed to treat jaundice in newborn babies. The company's technology specializes in avoiding light leakage and allows breathability to fine-tune the light distribution, and can be worn by the baby during breastfeeding, having skin-to-skin contact, and even when the baby is carried around, enabling parents to avoid phototherapy in NICU and treat jaundice.
- Sector
- Healthcare
- HQ
- Nijkerk, Netherlands
- Founded
- 2019
- Employees
- 7
- Website
- bilihome.org/
- Ownership
- Privately Held (backing)
Bilihome doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bilihome shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bilihome in its N-PORT filings yet. We sweep new filings monthly.